Today's Date: March 26, 2023
Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump   •   Philadelphia Works Names First Female Chief Operating Officer   •   AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers   •   Statement from the Chief Public Health Officer of Canada on World TB Day   •   SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t   •   HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio   •   Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail   •   Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference   •   National University Receives 2023 Military Friendly® Gold Designation   •   Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates   •   SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los   •   ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B   •   SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote   •   Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges   •   ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting   •   Build community with shared future, create better world   •   GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office   •   30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions
Bookmark and Share

Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team

PALO ALTO, Calif. , February 02 /Businesswire/ - Exai Bio announced today that it has added two new members to its executive leadership team — Emi Zychlinsky as Executive Vice President, Operations, and Seema Singh Bhan as Senior Advisor, Public Policy and External Affairs — to strengthen the company’s operational infrastructure and foster meaningful engagement with policymakers, regulators and advocacy organizations.

This press release features multimedia. View the full release here:

(Graphic: Business Wire)

(Graphic: Business Wire)

“Emi and Seema are deeply experienced and passionate industry leaders, and everyone on the Exai team is thrilled to welcome them to our team,” said Patrick Arensdorf, Chief Executive Officer of Exai. “Emi will help build processes and systems to help Exai grow quickly, deliberately and responsibly; Seema will lead our engagement with policymakers, regulators and advocacy organizations as we navigate this very dynamic healthcare space.”

Zychlinsky has more than 25 years of experience in the development of diagnostic tests from product concept to commercialization. She has a proven track record of building operational infrastructure and designing and implementing worldwide quality systems and regulatory strategies. Most recently, Zychlinsky served as Senior Vice President of Quality Assurance and Regulatory Affairs for the global team at Standard BioTools (formerly Fluidigm). Previous to this, she was Chief Technology Officer at Diadexus.

Singh Bhan brings more than two decades of experience in government affairs, public policy, and advocacy. She has a successful track record of bringing together diverse stakeholders, including policy makers, regulators, industry and advocacy groups, and academic leaders, to work on advancing breakthroughs in science and technology. Prior to joining Exai, Singh Bhan was Senior Vice President, Public Policy and External Affairs, at Thrive Early Detection Corp. Previously, she was Vice President, Head of Public Policy at Foundation Medicine, where she was instrumental in the success of the landmark parallel review decision by the FDA and CMS on next-generation sequencing for Foundation Medicine’s flagship product, FoundationOne CDx. Singh Bhan also spent well over a decade in public service, serving as Senior Counsel to the Senate Judiciary Committee and working with Senator Arlen Specter.

About Exai Bio

Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.

STORY TAGS: Photo/Multimedia, Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Personnel, California, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News